VOYAGER THERAP. DL -,001

At the Alzheimer’s Association International Conference, Voyager presented six-month toxicity data for VY1706: a single intravenous dose reduced tau protein in relevant brain regions of nonhuman primates by up to 75% and was well tolerated at the highest tested dose with no adverse findings in the CNS, spinal ganglia, or peripheral organs. The FDA granted an IND for VY1706 in June; the company plans to begin dosing adults with early-stage Alzheimer’s in the second half of the year. Analyses view Voyager as undervalued at $3.44 per share and a $208 million market capitalization, but note high cash burn despite a strong Current Ratio. » More on de.investing.com

Voyager Therapeutics obtained IND clearance from the FDA for VY1706, a siRNA-based tau-targeting gene therapy, allowing the company to start clinical trials in individuals with early Alzheimer’s. Dosages are expected to begin in the latter half of 2026. Voyager says VY1706 uses a TRACER AAV capsid with ALPL to deliver siRNA against MAPT mRNA and aims to durably reduce extracellular and intracellular tau after a single IV administration. » More on finance.yahoo.com

Voyager Therapeutics presented data showing its tau‑silencing gene therapy VY1706 reduced tau protein by up to 64% in non‑human primates and was well tolerated at all doses. The company plans to request FDA authorization for human trials in Q2 2026 and, if approved, aims for first‑in‑human dosing in the back half of 2026. Voyager also expects efficacy readouts for its anti‑tau antibody VY7523 in H2 2026 and ended Q1 2026 with $172 million in cash, which it says funds operations into 2028. » More on finance.yahoo.com